ReviewTransplant infectious disease : an official journal of the Transplantation Society
HHV-8/KSHV in Solid Organ Transplantation: Current Gaps of Knowledge and Future Directions.
Review in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Kaposi Sarcoma-Associated Herpesvirus Infection and Complications Among Solid Organ Transplant Recipients - United States, January 2021-September 2025.MMWR. Morbidity and mortality weekly report · 2026Article
- Donor-derived viral infections: the usual suspects and the new kids on the block.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The incidence of HHV-8/KSHV-associated diseases (KADs) among solid organ transplant (SOT) recipients has shown a relative increase, likely reflecting the growing population of long-term SOT survivors and heightened recognition and reporting due to greater clinician awareness. The real impact of HHV-8/KSHV in the SOT setting remains difficult to determine due to regional variations in seroprevalence and non-universal screening practices. Neoplastic KAD reported in SOT includes Kaposi sarcoma (KS), multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other rare lymphomas. Increasing attention has focused on Kaposi's Sarcoma-associated Herpesvirus Inflammatory Cytokine Syndrome (KICS), a non-malignant syndrome characterized by uncontrolled inflammation, fever, pancytopenia and elevated HHV-8/KSHV DNAemia, resembling viral sepsis that can progress to shock and multi-organ failure. A clinical protocol including testing donors and recipients, monitoring for DNAemia in recipients at risk, switching CNI to mTOR inhibitors, treatment with antivirals, and rituximab for KICS may mitigate the impact of HHV-8/KSHV infection in SOT recipients. However, standardized serological testing is not available and the role of monitoring, preemptive management and treatment of HHV-8/KSHV DNAemia should be studied in larger prospective studies. Severe donor-derived KICS and KS, often presenting without skin involvement, underscore the need for reliable serologic tests for identification of at-risk recipients (especially D+/R-), heightened clinical awareness to ensure timely diagnosis and prompt treatment. This review provides an updated overview of KADs with a particular focus on KICS in SOT, highlights knowledge gaps for future research, and summarizes recent advances in the screening and management of HHV-8/KSHV infection following transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.